| Name | Title | Contact Details |
|---|
Envisionier medical technologies Inc is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Biological Dynamics Inc. is an early stage company that has developed a proprietary AC Electrokinetic technology to rapidly extract nanoparticles in high-conductance physiological solutions. Biological Dynamics was founded in 2008 by Raj Krishnan and David Charlot, Bioengineering PHD graduates from the University of California, San Diego (UCSD). Our vision is to enable healthcare practitioners to detect, diagnose and monitor cancer and other diseases from a simple blood draw (or other bodily fluid) and rapidly intervene, increasing patient survivability while driving down the total burden costs.
Recognized as a disruptor in the health industry, dosist is setting a new standard in access to natural plant-based health and wellness solutions. Through our award-winning products, we provide consistent, targeted formulas and precise dosage, allowing people to experience the benefits of cannabis-based therapy in an effective and predictable way.
US HealthConnect is a Fort Washington, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.